▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3121 by analyst upside · 2026-08-13
AUPH
Aurinia Pharmaceuticals Inc.
Healthcare · Market Cap $2B · P/E 6.7x
ANALYST PRICE TARGET
+10.0%
implied upside to consensus target
Current Price $15.45
Consensus Target $17.0
Bull Target $20.0
Bear Target $15.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
3
Sell
0
52-Week Low $10.34
52-Week High $19.25
YTD Return +0.7%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 6.7x
Forward P/E 14.5x
EPS (TTM) $2.29
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $312M
Profit Margin 100.8%
52-WEEK RANGE
52-Week Low $10.34
52-Week High $19.25
Current Price $15.45
Bear Target $15.0
Bull Target $20.0
● Now $15.45 ● Target $17.0
TRADING DATA
Avg Volume 1.5M
YTD Return +0.7%
Analyst Count 7
Consensus Buy
Upside to Target +10.0%
Last Updated 2026-08-13

ANALYST SUMMARY

Aurinia Pharmaceuticals Inc. (AUPH) is currently trading at $15.45 with a Wall Street consensus price target of $17.0, implying potential upside of 10.0% over the next 12 months. 7 analysts currently cover AUPH, with a consensus rating of Buy - 57% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $20.0, while the most cautious has a target of $15.0.

AUPH operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 0.7% year-to-date and is currently trading near the upper end of its 52-week range of $10.34 – $19.25.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AVAH +15.5%
Aveanna Healthcare Holdings Inc.
$2B · P/E 7.5x · Buy
MD -1.3%
Pediatrix Medical Group, Inc.
$2B · P/E 12.7x · Hold
HRMY +15.9%
Harmony Biosciences Holdings, Inc.
$2B · P/E 12.9x · Buy
ADUS +14.1%
Addus HomeCare Corporation
$2B · P/E 20.5x · Buy
INSP +3.6%
Inspire Medical Systems, Inc.
$2B · P/E 12.9x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for AUPH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↓ Downgrade
Outperform → Market Perform 2025-12-03 29% win rate (7 calls)
Jefferies ↑ Upgrade
Hold → Buy 2025-11-07 50% win rate (6 calls)
RBC Capital ↓ Downgrade
Outperform → Sector Perform 2025-11-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2025-08-01 Building track record
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-16 40% win rate (10 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2024-09-09 40% win rate (10 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-09-06 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
47
out of 100
Coverage depth
16/30
Consensus clarity
24/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →